Mainz Biomed N.V. (NASDAQ: MYNZ)
$0.2020
-0.0104 ( -3.76% ) 2.2M
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Market Data
Open
$0.2020
Previous close
$0.2124
Volume
2.2M
Market cap
$12.90M
Day range
$0.1950 - $0.2150
52 week range
$0.1852 - $1.7900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Form 6-K | 5 | Nov 15, 2024 |
| 6-k | Form 6-K | 2 | Nov 12, 2024 |
| 6-k | Form 6-K | 2 | Oct 21, 2024 |
| 6-k | Form 6-K | 101 | Oct 18, 2024 |
| 6-k | Form 6-K | 3 | Oct 09, 2024 |
| 6-k | Form 6-K | 1 | Oct 03, 2024 |
| 6-k | Form 6-K | 3 | May 31, 2024 |
| 6-k | Form 6-K | 6 | Apr 24, 2024 |
| 6-k | Form 6-K | 3 | Apr 19, 2024 |
| 20-f | Annual reports | 121 | Apr 09, 2024 |